The downgrades from low-accuracy firms, while cautionary, are not statistically strong. Given consensus bullishness and improving EPS revisions, traders could view weakness toward $700 as a potential buying entry, but should wait for price stability or confirmation from a high-accuracy firm before committing.
Price Chart
Executive Summary
On May 18, 2026, two firms downgraded Regeneron Pharmaceuticals (REGN). Citigroup cut from Buy to Neutral, slashed price target from $900 to $700, nearly in line with the current $698.25. Leerink Partners downgraded from Outperform to Market Perform with a $641 target, implying ~8% downside. Both firms have below-average track records on REGN (Citi 43% accuracy on 7 calls, Leerink 50% on 2 calls). Consensus remains strongly bullish: 30 of 38 analysts (79%) rate Buy or Strong Buy, with a mean price target of $875.31 (25.4% upside). EPS revision momentum is positive, with 15 upgrades vs 6 downgrades for the next quarter. Insider sales are small and routine; institutional activity is mixed (Two Sigma trimming but Norges Bank adding a $1B position). While the cluster downgrade signals near-term caution, the positive consensus and earnings momentum suggest the stock may find support near $700. The low accuracy of the downgrading firms reduces the significance of this action.
Impact Score
Consensus & Targets
Consensus is heavily bullish: 30 of 38 analysts (79%) rate Buy or Strong Buy, 8 Hold (21%), and 0 Sell. The average price target is $875.31 with a median of $882.5. The downgrades are contrarian to the consensus view, which sees 25.4% upside from current levels.
Mean price target $875.31, median $882.5, high $1057, low $730. Current price $698.25 implies 25.4% upside to mean. Citigroup's new $700 PT of $700 is below the consensus low of $730, and Leerink's $641 is even lower. Both new targets are well below the consensus mean of $875.31, reflecting a more pessimistic view than the average analyst.
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-05-18 | JP Morgan | maintain | Overweight | $850.00 |
| 2026-05-18 | Piper Sandler | maintain | Overweight | $855.00 |
| 2026-05-18 | Wells Fargo | maintain | Equal-Weight | $700.00 |
| 2026-05-18 | RBC Capital | maintain | Sector Perform | $707.00 |
| 2026-05-18 | Citigroup | downgrade | Neutral | $700.00 |
| 2026-05-18 | Leerink Partners | downgrade | Market Perform | $641.00 |
| 2026-05-01 | Guggenheim | maintain | Buy | $995.00 |
| 2026-04-30 | RBC Capital | maintain | Sector Perform | $762.00 |
| 2026-04-30 | Barclays | maintain | Overweight | $917.00 |
| 2026-04-30 | Truist Securities | maintain | Buy | $796.00 |
In the last 30 days, REGN has seen 0 upgrades and 2 downgrades (these). EPS revisions for the current quarter are positive: 15 upward vs 6 downward in 30 days, with consensus rising $12.30 to $13.09. Full-year EPS also revised up 16 vs 7 down. This positive earnings momentum contrasts with the negative analyst action.
Firm Track Record — Citigroup
Citigroup accuracy: 55% on 4355 calls | avg return: 4.9%
Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 15 firms with ≥5 scored calls.
| Firm | Accuracy | Calls | Avg Return | vs Average |
|---|---|---|---|---|
| UBS | 67% | 4/6 | 5.1% | top tier |
| Canaccord Genuity | 57% | 4/7 | 9.4% | above average |
| TD Cowen | 50% | 1/2 | 3.1% | below average |
| Bernstein | 50% | 1/2 | 6.2% | below average |
| Cantor Fitzgerald | 50% | 4/8 | -4.5% | below average |
| BMO Capital | 50% | 3/6 | -3.7% | below average |
| Morgan Stanley | 50% | 5/10 | 4.1% | below average |
| Goldman Sachs | 50% | 1/2 | -3.6% | below average |
| Leerink Partners | 50% | 1/2 | -23.7% | below average |
| Evercore ISI Group | 50% | 1/2 | -4.9% | below average |
Citigroup has a 43% accuracy rate on 7 REGN calls, with an average return of 3.8% — below the average. Leerink is 50% on 2 calls with a -23.7% average return, the worst among all firms. The best performer is UBS (67% accuracy on 6 calls, +5.1% return); the worst by accuracy is RBC Capital (33% on 18 calls, -8.9%). Both downgrading firms are among the lowest in accuracy on this name.
Earnings Estimates
Next earnings: Jul 30, 2026
| Period | EPS Est. | EPS Range | Revenue | Revisions (7d) |
|---|---|---|---|---|
| 0q | $10.86 | $8.27 — $13.25 | $3.8B | ↑2 ↓0 |
| +1y | $48.20 | $41.10 — $60.05 | $17.6B | ↑2 ↓0 |
| +1q | $13.09 | $9.36 — $17.10 | $4.2B | ↑5 ↓0 |
| 0y | $46.50 | $38.82 — $53.61 | $15.9B | ↑6 ↓0 |
Cross-Platform Signals
Insider sales are small ($10k by CFO Ryan in April/May, $38k by director Zoghbi in February) and likely routine; no informative cluster. Congressional: Rep. Khanna bought $1k‑$15k in April — negligible. Institutional actions are mixed: Two Sigma trimmed 40% and Renaissance near-exited (‑97%), but Norges Bank initiated a $1B market position and Sound Shore added 53%. Short interest is not available. Overall, the downgrade divergence with still‑positive institutional buying and upward EPS revisions, reducing the joint signal reliability of the bearish signal.
Investment Themes
Documents Analyzed
Report based on filing metadata.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 1d ago | ANALYST-UPGRADE | — | awaiting T+20 | — | — |
Sep 3, 2026 29d ago | Insider Cluster | $843.47 $735.20 | ▼ −12.84% | ▼ −11.65% | $735.20 (−12.84%) |
Aug 24, 2026 5w ago | Court Ruling | $828.50 $803.90 | ▼ −2.97% | ▼ −4.28% | $735.20 (−11.26%) |
Aug 20, 2026 6w ago | Press Release | $826.64 $784.85 | ▼ −5.06% | ▼ −5.06% | $735.20 (−11.06%) |
Aug 12, 2026 7w ago | Insider Cluster | $797.99 $793.26 | ▼ −0.59% | ▲ +1.30% | $735.20 (−7.87%) |
Aug 11, 2026 7w ago | Court Ruling | $797.00 $807.65 | ▲ +1.34% | ▲ +2.40% | $735.20 (−7.75%) |
Jul 30, 2026 9w ago | 8-K | $738.34 $807.71 | ▲ +9.40% | ▲ +5.43% | $735.20 (−0.43%) |
Jul 30, 2026 9w ago | Press Release | $738.34 $807.71 | ▲ +9.40% | ▲ +5.43% | $735.20 (−0.43%) |
Jul 27, 2026 9w ago | Press Release | $695.18 $833.56 | ▼ −19.91% | ▼ −16.52% | $735.20 (−5.76%) |
Jul 17, 2026 11w ago | Press Release | $676.69 $800.70 | ▲ +18.33% | ▲ +13.88% | $735.20 (+8.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access